header logo image


Page 737«..1020..736737738739..750760..»

Siah2 protein discovered as a regulator of the immune system – Drug Target Review

January 8th, 2020 11:45 pm

A new study has revealed that the Siah2 protein is crucial to control Tregs in mice, which can reduce the effectiveness of immunotherapies.

Researchers have identified a new technique to improve the immune systems ability to fight cancer. Using mouse models they demonstrated that the Siah2 protein is essential to control T regulatory cells (Tregs), which can limit the effectiveness of currently used immunotherapies.

The study was conducted at the Sanford Burnham Prebys Medical Discovery Institute, in collaboration with NYU Langones Perlmutter Cancer Center, both US.

While Siah2 is involved in control of activities that govern cancer development, this study offers the first direct evidence for its role in the immune system, namely in anti-tumor immunity, says Dr Zeev Ronai, professor in Sanford Burnham Prebys Tumor Initiation and Maintenance Program and senior author of the study. Our study shows that a PD-1 inhibitor can be used to treat tumors that currently do not respond to this therapy, when administered in mice lacking the Siah2 gene, thereby offering a means to expand the effectiveness of immunotherapy. The findings also provide further justification for our efforts to find a drug that blocks Siah2.

In the study, the scientists used genetically engineered mice that did not produce the Siah2 protein and then introduced BRAF-mutant melanoma, a mutation that occurs in about half of human melanomas. This approach allowed the researchers to study the role of Siah2 in the tumours microenvironment, of which the immune system is a major component. In the absence of the Siah2 gene, the melanoma tumors receded, which contrasted to mice with the Siah2 gene, in which the tumour continued to grow. Giving these mice anti-PD-1 therapy effectively eliminated melanoma that otherwise resisted this therapy, demonstrating a new path to enhance the effectiveness of current immunotherapies.

The scientists discovered that in the Siah2 mutant mice, the tumours were infiltrated by killer but not Treg immune cells, indicating the immune system was more active in clearing the tumours. The lack of the Treg cells was attributed to reduced proliferation and recruitment into the tumour due to the role of Siah2 and its control of cell cycle regulatory proteins.

Ronai explains: In our study, mice lacking the Siah2 gene were able to mount an immune attack against melanoma. Moreover, the effectiveness of Siah2 in immunotherapy was demonstrated for cold tumors those that do not respond to immunotherapy which were effectively eliminated by a PD-1 blockade in Siah2-mutant mice.

The researchers say that their findings offer a new means to make immunotherapies more effective in individuals who do not respond to anti-PD-1 therapy.

The findings were published in Nature Communications.

Read the rest here:
Siah2 protein discovered as a regulator of the immune system - Drug Target Review

Read More...

Body clock affects how the immune system works — new findings – The Conversation UK

January 8th, 2020 11:45 pm

All life on Earth has evolved to cope with a rotating planet which results in the predictable transition between day and night. The details differ between plants, fungi, bacteria and animals, but the consistent feature is a biological clock that allows the organism to anticipate the change and prepare for it.

In animals, the central clock that keeps track of night and day is in the brain where it receives light from the retina to keep synchronised with the light or dark. But all cells in the body have their own clocks. Because these biological clocks have a cycle that is close to 24 hours they are termed circadian (circa meaning about and dian, meaning day, from the Latin dies).

We now live with cheap, bright, artificial light, shift-work, sleep-deprivation and jet-lag all major challenges to the ancient circadian control mechanisms in our bodies. All these circadian and sleep challenges are associated with disease. But in our latest study, using mice, we discovered that infections at different times of the day cause different severity of disease.

Read more: The ancient clock that rules our lives and determines our health

Surprisingly, we found that the clock ticking in the cells of the immune system was responsible for the change in response to bacterial infection. In particular, specialised cells called macrophages, which are big cells that engulf and kill bacteria.

Macrophages, either growing in a dish or in a mouse, responded differently at different times of the day. And disabling the clock in these cells resulted in super macrophages, which moved faster and ate more bacteria than the normal macrophages.

We found that clockless macrophages protected mice from bacterial infection with many types of bacteria. A closer look at the macrophages revealed that the cells looked different, with a major change in the structural proteins that maintain the cell shape and are needed for cell movement and for eating bacteria. The change in the cells internal architecture, or cytoskeleton, became a focus of our studies.

We discovered that the macrophage circadian clock directly controlled the components of the cytoskeleton. We saw changes in the amount of cytoskeletal protein building blocks, and also in the activity of a master regulator of cytoskeletal change. This master regulator is a protein called RhoA.

RhoA is activated by bacterial contact and drives the macrophage to move and consume bacteria. We found that RhoA was active in the clockless macrophages even when no bacteria were present. When bacteria contacted the normal macrophages RhoA became active, but there was no further change in the clockless macrophages, as the RhoA was already active. So the clockless macrophages were always switched on, and so able to respond to bacterial attack more rapidly.

To find out how the clock was changing the behaviour of macrophages, we turned to the core clock mechanism. This comprises a small group of proteins that change in abundance through time, so allowing the cells to tell the time. We found that one of these clock factors, called BMAL1, was the essential link between the clock and the macrophage behaviour.

One of the major issues facing the modern world is the growing resistance of bacteria to antibiotics. There have been no new classes of antibiotics for 30 years. Bacterial resistance to antibiotics means that we have untreatable infections and face a future where surgery will become riskier.

Read more: What will happen when antibiotics stop working?

Finding new ways to enhance defence against bacteria is a high priority. Discovery of a circuit linking the clock to bacterial defence opens up a new route to reduce our reliance of the limited range of existing antibiotics. It may be possible to enhance natural defences to bacterial infection by targeting the clock.

The operation of the circadian clock can be altered by light exposure, by changing meal times, by genetic variability within human populations and by new drugs capable of regulating this system. One problem with targeting the clock with drugs is that the impact on other systems will be broad and the consequences hard to predict. But short-term intervention to boost immunity to infection may offer benefits, at low cost.

Similarly, reinforcing the circadian rhythm of high-risk people, in hospitals for example, by controlling lighting and meal times may boost immunity and prevent hospital-acquired infections.

See more here:
Body clock affects how the immune system works -- new findings - The Conversation UK

Read More...

Yisheng and Tavotek to co-develop combination therapy for cancer – BioWorld Online

January 8th, 2020 11:45 pm

BEIJING Yisheng Biopharma Co. Ltd., of Beijing, said it has inked a pact with U.S. biotech Tavotek Biotherapeutics, of Ambler, Pa., to co-develop a combination therapy with Yishengs YS-ON-001/002 and Tavoteks Tavo-301/303, which the companies hope could prove a more efficacious cancer treatment than the popular anti-PD-1/PD-L1 monotherapies.

YS-ON-001 and YS-ON-002 are potent agonists of TLR3, MDA5 and RIG-I pathways. Meanwhile, Tavo-301/303 is a series of novel multispecific antibody-based immuno-oncology assets.

Our approach allows us to develop a combination therapy that can activate the immune system differently from PD-1/PD-L1-based molecules, Yishengs CEO David Shao told BioWorld.

He added that current immune-oncology approaches such as PD-1/PD-L1 antibodies as a single agent achieve only around 20% to 30% response rates in clinical settings.

By combining YS-ON-001/002 with multispecific antibodies like Tavo-301/303 directed against tumors, the two companies hope they can develop a first-in-class immunotherapy with potentially higher response rates.

We may find a very good application of this combination for different types of solid tumor, such as lung cancer, breast cancer and liver cancer, he said, adding that the two drug candidates can create synergy.

Shao also revealed to BioWorld that both companies aim to move this combination approach into clinical development in 2021, potentially in multiple countries, including China and the U.S.

Chinese biotechs have started to look beyond PD-1/PD-L1 antibodies as monotherapies, as the country has approved six of them so far and the craze for them has cooled down.

PD-1/PD-L1 antibodies as monotherapy is the first-generation approach. Right now, people are working on the second generation, such as bispecific antibodies, in order to improve the response rate for different tumor types, he added.

According to Yisheng, YS-ON-001 and YS-ON-002 have demonstrated promising effects in activating the innate and adaptive immune systems and modulating the tumor microenvironment. They can reduce the immunosuppressive effects of tumor microenvironments and enhance antitumor immune responses.

Currently in a phase I trial in China and Singapore, YS-ON-001 has shown a good safety profile to date. It also received orphan drug designations from the FDA for the treatment of pancreatic and liver cancers. The drug candidate can be delivered via intramuscular, subcutaneous or intratumoral injection.

In preclinical studies, YS-ON-001 was found to significantly increase the proportion of natural killer and natural killer T cells in addition to increasing CD4+ and CD8+ T-cell responses. The drug candidate also reduced the number of T regulatory cells and myeloid-derived suppressor cells in some tumor models.

Meanwhile, YS-ON-002 is in the IND-ready stage. It was found to significantly enhance the expression levels of PD-L1 in tumor cells, proving the rationale for combination therapy with PD-1 antibodies.

Yisheng has said it believes that YS-ON-001/002 could prove to be integral immunotherapy components of standard oncology care, joining other therapies such as chemotherapies, targeted therapies and checkpoint inhibitors or emerging immunotherapies for additive or synergistic treatment benefits.

Both compounds were developed using the companys PIKA immunomodulating technology, which augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Through TLR3, RIG-I and MDA-5 signaling, PIKA technology can enable the prompt production of interferon, cytokines, chemokines and co-stimulatory factors. Producing type I interferon using PIKA administration can facilitate antigen cross-presentation by dendritic cells, while augmenting CD4+ T-cell, CD8+ T-cell and natural killer cell responses. That makes PIKA-based therapeutics suitable for both antiviral and antitumor applications.

Our PIKA technology platform has achieved proof-of-concept results in phase I and phase II trials. It has demonstrated a good result in activating human immune system in clinical trials, Shao said.

He revealed to BioWorld that in the companys immune-oncology pipeline, a third drug candidate is being developed to target human papillomavirus-induced cancer.

What is intriguing is that Yisheng is better known as a vaccine maker, with four known assets in its vaccine pipeline.

Using the same PIKA technology platform, Yisheng has developed hepatitis B vaccine YS-HBV-001 and the PIKA rabies vaccine for accelerated protection against rabies infection.

Its most advanced asset is the YSJA rabies vaccine, which has been marketed already. It is also developing YS-HBV-002 for chronic hepatitis B treatment.

Its new U.S. partner, Tavotek, however, has kept a lower profile, with an undisclosed pipeline. It is known for extensive work on multispecific antibodies and advanced technology platforms with a focus on cancers, autoimmune conditions and infectious diseases.

Its Tavoselect platform, which the company used to develop Tavo-301/303, is designed to offer highly diversified human antibody sequences that can be utilized in different formats, such as multispecific antibodies. It is said to be able to capture and optimize the best candidates rapidly with NGS analyses and AI.

Tavotek also has three technology platforms for biologics, namely the Targeted Biologics Engineering Platform to develop monoclonal and multispecific antibodies against unique targets; the Tavo-Immune Modulator Platform to enable novel synthetic biologic design for auto-immune diseases and chronic viral infections; and the Multicyclic Intracellular Peptide Platform to develop unique multicyclic peptides with great potency targeting intracellular protein-protein interactions.

The partnership with Yisheng is the first that the U.S. biotech has unveiled, and the collaboration could go beyond oncology.

Continued here:
Yisheng and Tavotek to co-develop combination therapy for cancer - BioWorld Online

Read More...

Can a Flu Shot Be Used to Improve Cancer Immunotherapies? – BioSpace

January 8th, 2020 11:45 pm

Researchers with Rush University Medical Center injected tumors with flu vaccines, even some FDA-approved seasonal flu shots, and found that this attracted immune cells to attack the tumors. In the language of immuno-oncology, it turned cold tumors, which dont cause much of an immune reaction, hot. The research was published in the Proceedings of the National Academy of Sciences.

We wanted to understand how our strong immune responses against pathogens like influenza and their components could improve our much weaker immune response against some tumors, said Andrew Zloza, assistant professor in Rush Medical Colleges Department of Internal Medicine and senior author of the study.

Some immunotherapies against cancer leverage live pathogens, but they havent shown lasting effects in most patients or cancer types. Pulling data from a National Cancer Institute database, the research team found that lung cancer patients who had been hospitalized for a lung infection caused by influenza at the same time lived longer than lung cancer patients who had no flu. They ran experiments and found similar results in mice with tumors and flu lung infections.

However, there are many factors we do not understand about live infections, and this effect does not repeat in tumors where influenza infections do not naturally occur, like skin, Zloza said.

So they worked with an inactivated flu virus, which is basically a flu vaccine. A direct injection of this vaccine into the skin melanoma of the mice caused the tumors to either shrink or grow slower. It appears to increase the proportion of dendritic cells in the tumor, which are immune-stimulating cells. This resulted in an increase in CD8+ T-cells, which recognize and kill cancer cells.

In addition, injecting the vaccine into the skin melanoma tumor on one side of the body also reduced growth of a second skin tumor on the other side of the mouses body that had not been injected. This means that the vaccine, although dosed locally, had a systemic effect.

The researchers also observed similar systemic results in a mouse model of metastatic triple-negative breast cancer where it reduced the primary tumor but also the metastasis of the breast tumor to the lungs.

Based on this result, Zloza said, we hope that in patients, injecting one tumor with an influenza vaccine will lead to immune responses in their other tumors as well. Our successes with a flu vaccine that we created made us wonder if seasonal flu vaccines that are already FDA-approved could be repurposed as treatments for cancer.

He went on to add, Since these have been used in millions of people and have already been shown to be safe, we thought using flu shots to treat cancer could be brought to patients quickly.

And their experiments showed that they did. Additional experiments involved a mouse model called AIR-PDX, where they implanted tumor cells and immune cells from a cancer patient into a mouse that didnt have a functioning immune system of its own. This prevents the mouse from rejecting the implanted cells. They used a human lung tumor and a melanoma metastasis in their AIR-PDX models. What they found was that injecting the flu shot into the patient-derived tumors also caused them to shrink, while the untreated tumors continued to grow.

They also ran experiments using checkpoint inhibitors, a type of immuno-oncology treatment, such as Mercks Keytruda (pembrolizumab). The flu vaccines reduced cancer growth alone whether the tumor was responsive to checkpoint inhibitors or not. And when they combined the flu vaccine with a checkpoint inhibitor, they showed an even greater decrease in tumor growth.

These results propose that eventually both patients who respond and who do not respond to other immunotherapies might benefit from the injection of influenza vaccines into the tumor, and it may increase the small proportion of patients that are now long-term responders to immunotherapies, Zloza said.

The researchers used five different flu shots from the 2017-2018 flu season in their research, and four were effective in fighting tumors.

The next step is to plan clinical trials. Because the flu vaccine is already FDA approved, the study time may be shorter.

Here is the original post:
Can a Flu Shot Be Used to Improve Cancer Immunotherapies? - BioSpace

Read More...

Molecular mechanism suggests new ways to bolster immunity to deadly rotavirus: U of T researchers – News@UofT

January 8th, 2020 11:45 pm

Researchers at the University of Toronto have discovered how a brief disruption to a molecular pathway in the guts of mice before they are born can compromise immunity in adulthood to a common and often deadly intestinal virus.

The researchers found that in utero inhibition of molecular signalling in the lymphotoxin pathway, long known as important in the development of the immune system, prevented a robust antibody response in adult mice to rotavirus. In humans, rotavirus causes an estimated 215,000 deaths annually, mostly in the developing world.

That early disruption limits the ability of the immune system to later trigger and generate production of Immunoglobulin A (IgA) antibodies, the researchers showed. It also interferes with the nature and function of cells in the gut that support the antibody response, called mesenteric lymph node stromal cells.The research was recently published in the journal Science Immunology.

It was surprising that these non-immune stromal cells were so important to the immune response, saysJennifer Gommerman, a professor ofimmunologyin U of Ts Faculty of Medicine and principal investigator on the study.

It turns out that stromal cells affect the ability of immune B cells to produce IgA that neutralizes rotavirus. Were just beginning to understand the influence these stromal cells can have.

Gommerman says the findings highlight the growing importance of research on the environment in which immune cells function. We typically think of a lymph node as just a bag of lymphocytes, but there is also this supporting structure that clearly has an active role in shaping immunity.

The studys first author, post-doctoral researcherConglei Li, identified a broad subset of stromal cells that affect the immune response to rotavirus. But the key players are likely a subset of that subset, Gommerman says. New technology known as single-cell RNA sequencing should soon enable researchers to identify many more of those cells, she adds.

That work could, in turn, lead to a better understanding of the genetic and environmental factors that may undermine immunity to rotavirus in the developing world, where rotavirus vaccines are much less effective than in high-resource settings.

Gommerman says that while several dysfunctions in the immune system likely contribute to reduced immunity to rotavirus in low-income countries, the current study offers a hint that prevention may be possible.

The thinking would be that if youre pregnant in a resource-depleted area, you may take a dietary supplement at a specific point to ensure proper development of tissues that support immunity, and which enable a vaccine to be more effective, she says.

That kind of intervention is likely a long way off, adds Gommerman, and replicating her results in human pregnancy presents obvious ethical problems. A more immediate next step for her lab is a collaborative study on IgA immune responses to other pathogens such as norovirus, another highly contagious disease.

A focus on single pathogens is useful in studies of IgA, according to Gommerman, because so many factors can influence IgA response. If you simplify the system of study, you get more predictable kinetics and can ask more discrete questions, she says. Weve made a contribution with that approachon a question that has been percolating in several labs for years. That feels good.

The research received support from the Canadian Institutes of Health Research, Princess Margaret Cancer Foundation and the Swiss National Science Foundation.

Read the original:
Molecular mechanism suggests new ways to bolster immunity to deadly rotavirus: U of T researchers - News@UofT

Read More...

Virus Spread by Shrews Linked to Human Deaths from Mysterious Brain Infections – Scientific American

January 8th, 2020 11:45 pm

Borna disease virus 1 (BoDV-1) causes a bizarre and deadly neurological infection in horses, sheep and other domesticated mammals in parts of Germany, Switzerland, Liechtenstein and Austria. Borna disease was named after a city in eastern Germany where it once killed numerous horses in the late 19th century. Infected animals have been known to engage in strange behaviors, such as smashing their heads into things, as well aspipe smokingan informal term for when animals are eating hay and suddenly stop chewing mid-mouthful, with the uneaten portion protruding like a pipe. But the disease does not appear to spread between horses; they are thought to acquire it from shrews, which can live in hay and secrete or excrete fluids containing the virus.

About 14 years ago, researchers identified the bicolored white-toothed shrew as a reservoir hostan organism in which a virus replicates but does not usually cause illnessfor BoDV-1. Horses and sheep are considered dead-end hosts that cannot spread the pathogen. For decades, scientists had debated whether the virus is zoonotic, or capable of jumping from animals to humans. Several studies even suggested that it might be present in people with psychiatric disorders such as depression, schizophrenia and bipolar disorder. It was later shown, however, that the viral RNA sequences detected in these studies were likely the result of laboratory contamination, and research on human infections subsided.

But in 2015 a related type of bornavirus found in exotic squirrels was implicated in at least four human deaths. Then, between 2018 and 2019, scientists detected the classical bornavirus, BoDV-1, in five people in Germany who suffered serious or fatal encephalitis (brain inflammation caused by infection)three of whom were recipients of organ transplants and were taking drugs to suppress their immune system. Now, in a study published Tuesday in Lancet Infectious Diseases, researchers have reported eight additional cases of BoDV-1 infection in humans who died of encephalitis. The pathogen appears to have flown under the radar for decades, but the researchers say doctors should be considering it a potential cause in such deaths.

We now have eight more cases, and these provide additional material for a better understanding of the disease, says Martin Beer, head of the Institute of Diagnostic Virology at the Friedrich Loeffler Institute in Germany, who was co-senior author of the new study and was also part of the team that reported the squirrel bornavirus infections. The findings confirm that the virus can infect humans and cause deadly encephalitis. But the risk is, to our opinion, pretty low, Beer says.

Beer and his colleagues analyzed postmortem brain tissue from 56 patients in southeastern Germanys state of Bavaria between 1999 and 2019. The samples were tested for genetic material from BoDV-1, which the researchers verified by additional testing for antibodies to it. Seven out of nine patients who died of encephalitis of unknown cause at one diagnostic center later tested positive for the virus (one of these cases had been reported previously). An additional two cases that tested positive were also included in the analysis.

The results confirm the virus had caused eight new encephalitis cases; two of these were immune-compromised individuals who had received organ transplants, and six were not. Because other recipients of organs from the same donor did not test positive for the virus, researchers think the transplant recipients that died from the virus probably acquired it from being immune-compromised, not from the donor. The patients suffered symptoms including headache, fever and confusion, which later progressed to coma and ultimately death.

All of the patients lived in rural areas and worked or spent a lot of time outside. Most had also been around cats, which are known to catch shrews and sometimes present them to their owners. Beer and his team hypothesize that the patients were exposed to BoDV-1 this way or perhaps by inhaling dust containing dried shrew urine. Future research will be needed to determine the exact infection route, he says.

Once in a human or horse host, the virus is thought to cross the blood-brain barrier into the central nervous system, where it triggers the hosts immune system to attack brain tissue. Its not the virus killing the brain cell or nerve tissue, Beer explains. Its the [hosts] own immune system recognizing the infection and starting to kill parts of brain.

There is no known treatment for the disease, but researchers are exploring whether antivirals such as ribavirinwhich has been shown to kill a range of bornaviruses in cells grown in a dish and in animal studiescould be effective in treating BoDV-1 infections in humans. Beer and his colleagues have plans to test newer antivirals against the virus in animal studies.

I think its an excellent paper, says Norbert Nowotny, a professor of virology at the University of Veterinary Medicine, Vienna, who was not involved in the new study but was part of the group that discovered shrews were a reservoir host for the virus. This Borna disease is really a strange diseaseits not like a flu, he adds, noting that it does not cause epidemics. Its a single-animal disease, and it seems to be the same in humans.

The virus itself is somewhat unusual in that it has a very short genome and makes only a few proteins. It does not seem to infect many individualsbut when it does, it kills them very efficiently. Numerous other zoonotic viruses infect many people but are seldom deadly. Previous research has found that humans and most mammals actually have bornavirus sequences in their genomes, which may help organisms protect themselves against infection, some hypothesize.

Fortunately, the virus does not appear to be transmitted between humans. I think we are all happy that this is not a virus that can spread easily, Beer says. But in light of these new findings, doctors should consider BoDV-1 as a possible cause of encephalitis in areas where it has been known to infect humans and horses.

Read more from the original source:
Virus Spread by Shrews Linked to Human Deaths from Mysterious Brain Infections - Scientific American

Read More...

Cleveland Clinic Childrens Hospital sees rise in cases of respiratory illness RSV – cleveland.com

January 8th, 2020 11:45 pm

CLEVELAND, Ohio Cleveland Clinic Childrens Hospital is seeing a significant rise in cases of respiratory syncytial virus, or RSV, an illness that causes respiratory tract infections in infants.

Most of the children hospitalized for RSV at the Clinic have been less than 2 years old, and some are as young as 6 months, said Dr. Camille Sabella, head of the Center for Pediatric Infectious Diseases at the childrens hospital.

In adults and older, healthy children, RSV symptoms are mild and typically mimic the common cold.

But RSV can cause severe infection in some people, especially premature babies, older adults, infants and adults with heart and lung disease, or anyone with a very weak immune system.

RSV is the most frequent cause of bronchiolitis inflammation of the small airway passages entering the lungs in infants and young children. The illness accounts for approximately 125,000 hospitalizations and 250 infant deaths every year in the United States, according to an American Academy of Pediatrics study.

The virus typically begins circulating in the fall, and peaks in January or February. This is prime season, Sabella said.

As of December, visits to the Clinics pediatric emergency department for flu and RSV were up 20% over December 2018, Sabella said. Numbers for RSV cases alone were not available.

The Clinic is also seeing a rise in flu cases, it reported Wednesday. Having peaks in both influenza and RSV results in more hospitalizations and emergency department visits, Sabella said.

At University Hospitals, the number of RSV cases declined for the week ending Jan. 4, as compared with previous weeks, the hospital system reported. Flu activity was also slightly lower from a peak seen during the week of Dec. 22-28.

Dr. Amy Ray, director of infection prevention at MetroHealth, said in a statement that the hospital system is seeing patients with symptoms that include fever, sore throat, cough and body aches. Many are being tested for both influenza and RSV.

The number of RSV diagnoses hit 80 five weeks ago and have been stable around 60 or 70 for the following four weeks, Ray said.

MetroHealth is still seeing widespread cases of flu. Flu season usually peaks around late January but its not certain when it will peak this year, Ray said.

Hospitals are not required to report cases of RSV to county health officials. However, the percentage of emergency department visits for congestion and/or cough was at an eight-year high last week, according to the Cuyahoga County Board of Health.

RSV spreads through direct person-to-person contact and can live on surfaces, Sabella said. Unlike the flu virus, the RSV virus does not survive in the air.

Premature babies or infants and adults who have chronic heart or lung problems may get a severe case of RSV, according to the Mayo Clinic website. Symptoms of severe RSV infection in infants include short, shallow and rapid breathing; cough; lack of appetite; tiredness; and irritability.

There is no vaccine to prevent RSV. Ways to stop the spread of the virus include disinfecting surfaces and shared toys, covering coughs and sneezes with an elbow, washing hands frequently and avoiding touching the face and eyes.

Go here to see the original:
Cleveland Clinic Childrens Hospital sees rise in cases of respiratory illness RSV - cleveland.com

Read More...

Intensity Therapeutics to Participate in East/West CEO Conference – Business Wire

January 8th, 2020 11:45 pm

WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that Lewis H. Bender, President and CEO, will be a featured panelist on the Developments in The Oncology Landscape panel at East/West CEO. The conference will take place January 11-12, 2020, the weekend before the 38th Annual J.P. Morgan Healthcare Conference, at the Four Seasons Hotel in San Francisco.

The panel, which will examine the next wave of innovations and developments in oncology, will be held on Sunday, January 12, 2020 from 1:45 p.m. to 2:15 p.m. PST.

About Intensity Therapeutics

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRxSM technology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensitys product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors. The Company executed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institutes (NCI) Vaccine Branch in 2014. The Company is also collaborating with Merck Sharpe & Dohme to evaluate the combination of INT230-6, Intensitys lead product candidate, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced solid malignancies. For more information, please visit http://www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.

Forward Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Read the original:
Intensity Therapeutics to Participate in East/West CEO Conference - Business Wire

Read More...

The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub

January 8th, 2020 11:45 pm

Last year left us with this piece of bombshell news: He Jiankui, the mastermind behind the CRISPR babies scandal, has been sentenced to three years in prison for violating Chinese laws on scientific research and medical management. Two of his colleagues also face prison for genetically engineering human embryos that eventually became the worlds first CRISPRd babies.

The story isnt over: at least one other scientist is eagerly following Hes footsteps in creating gene-edited humans, although he stresses that he wont implant any engineered embryos until receiving regulatory approval.

Biotech stories are rarely this dramatic. But as gene editing tools and assisted reproductive technologies increase in safety and precision, were bound to see ever more mind-bending headlines. Add in a dose of deep learning for drug discovery and synthetic biology, and its fair to say were getting closer to reshaping biology from the ground upboth ourselves and other living creatures around us.

Here are two stories in biotech were keeping our eyes on. Although successes likely wont come to fruition this year (sorry), these futuristic projects may be closer to reality than you think.

The idea of human-animal chimeras immediately triggers ethical aversion, but the dream of engineering replacement human organs in other animals is gaining momentum.

There are two main ways to do this. The slightly less ethically-fraught idea is to grow a fleet of pigs with heavily CRISPRd organs to make them more human-like. It sounds crazy, but scientists have already successfully transplanted pig hearts into baboonsa stand-in for people with heart failurewith some recipients living up to 180 days before they were euthanized. Despite having foreign hearts, the baboons were healthy and acted like their normal buoyant selves post-op.

But for cross-species transplantation, or xenotransplants to work in humans, we need to deal with PERVsa group of nasty pig genes scattered across the porcine genome, remnants of ancient viral infections that can tag along and potentially infect unsuspecting human recipients.

Theres plenty of progress here too: back in 2017 scientists at eGenesis, a startup spun off from Dr. George Churchs lab, used CRISPR to make PERV-free pig cells that eventually became PERV-free piglets after cloning. Then last month, eGenesis reported the birth of Pig3.0, the worlds most CRISPRd animal to further increase organ compatibility. These PERV-free genetic wonders had three pig genes that stimulate immunorejection removed, and nine brand new human genes to make themin theorymore compatible with human physiology. When raised to adulthood, pig3.0 could reproduce and pass on their genetic edits.

Although only a first clinical propotype that needs further validation and refinement, eGenesis is hopeful. According to one (perhaps overzealous) estimate, the first pig-to-human xenotranplant clinical trial could come in just two years.

The more ethically-challenged idea is to grow human organs directly inside other animalsin other words, engineer human-animal hybrid embryos and bring them to term. This approach marries two ethically uncomfortable technologies, germline editing and hybrids, into one solution that has many wondering if these engineered animals may somehow receive a dose of humanness by accident during development. What if, for example, human donor cells end up migrating to the hybrid animals brain?

Nevertheless, this year scientists at the University of Tokyo are planning to grow human tissue in rodent and pig embryos and transplant those hybrids into surrogates for further development. For now, bringing the embryos to term is completely out of the question. But the line between humans and other animals will only be further blurred in 2020, and scientists have begun debating a new label, substantially human, for living organisms that are mainly human in characteristicsbut not completely so.

With over 800 gene therapy trials in the running and several in mature stages, well likely see a leap in new gene medicine approvals and growth in CAR-T spheres. For now, although transformative, the three approved gene therapies have had lackluster market results, spurring some to ponder whether companies may cut down on investment.

The research community, however, is going strong, with a curious bifurcating trend emerging. Let me explain.

Genetic medicine, a grab-bag term for treatments that directly change genes or their expression, is usually an off-the-shelf solution. Cell therapies, such as the blood cancer breakthrough CAR-T, are extremely personalized in that a patients own immune cells are genetically enhanced. But the true power of genetic medicine lies in its potential for hyper-personalization, especially when it comes to rare genetic disorders. In contrast, CAR-Ts broader success may eventually rely on its ability to become one-size-fits-all.

One example of hyper-tailored gene medicine success is the harrowing story of Mila, a six-year-old with Batten disease, a neurodegenerative genetic disorder that is always fatal and was previously untreatable. Thanks to remarkable efforts from multiple teams, however, in just over a year scientists developed a new experimental therapy tailored to her unique genetic mutation. Since receiving the drug, Milas condition improved significantly.

Milas case is a proof-of-concept of the power of N=1 genetic medicine. Its unclear whether other children also carry her particular mutationBatten has more than a dozen different variants, each stemming from different genetic miscodingor if anyone else would ever benefit from the treatment.

For now, monumental costs and other necessary resources make it impossible to pull off similar feats for a broader population. This is a shame, because inherited diseases rarely have a single genetic cause. But costs for genome mapping and DNA synthesis are rapidly declining. Were starting to better understand how mutations lead to varied disorders. And with multiple gene medicines, such as antisense oligonucleotides (ASOs) finally making a comeback after 40 years, its not hard to envision a new era of hyper-personalized genetic treatments, especially for rare diseases.

In contrast, the path forward for CAR-T is to strip its personalization. Both FDA-approved CAR-T therapies require doctors to collect a patients own immune T cells, preserved and shipped to a manufacturer, genetically engineered to boost their cancer-hunting abilities, and infused back into patients. Each cycle is a race against the cancer clock, requiring about three to four weeks to manufacture. Shipping and labor costs further drive up the treatments price tag to hundreds of thousands of dollars per treatment.

These considerable problems have pushed scientists to actively research off-the-shelf CAR-T therapies, which can be made from healthy donor cells in giant batches and cryopreserved. The main stumbling block is immunorejection: engineered cells from donors can cause life-threatening immune problems, or be completely eliminated by the cancer patients immune system and lose efficacy.

The good news? Promising results are coming soon. One idea is to use T cells from umbilical cord blood, which are less likely to generate an immune response. Another is to engineer T cells from induced pluripotent stem cells (iPSC)mature cells returned back to a young, stem-like state. A patients skin cells, for example, could be made into iPSCs that constantly renew themselves, and only pushed to develop into cancer-fighting T cells when needed.

Yet another idea is to use gene editing to delete proteins on T cells that can trigger an immune responsethe first clinical trials with this approach are already underway. With at least nine different off-the-shelf CAR-T in early human trials, well likely see movement in industrialized CAR-T this year.

Theres lots of other stories in biotech we here at Singularity Hub are watching. For example, the use of AI in drug discovery, after years of hype, may finally meet its reckoning. That is, can the technology actually speed up the arduous process of finding new drug targets or the design of new drugs?

Another potentially game-changing story is that of Biogens Alzheimers drug candidate, which reported contradicting results last year but was still submitted to the FDA. If approved, itll be the first drug to slow cognitive decline in a decade. And of course, theres always the potential for another mind-breaking technological leap (or stumble?) thats hard to predict.

In other words: we cant wait to bring you new stories from biotechs cutting edge in 2020.

Image Credit: Image by Konstantin Kolosov from Pixabay

See the original post here:
The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub

Read More...

A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN – Dove Medical Press

January 8th, 2020 11:44 pm

Yaser H Gholami, 1 4 Lee Josephson, 3 Eman A Akam, 5 Peter Caravan, 5 Moses Q Wilks, 3 Xiang-Zuo Pan, 3, 6 Richard Maschmeyer, 1 Aleksandra Kolnick, 3, 7 Georges El Fakhri, 3 Marc D Normandin, 3 Zdenka Kuncic, 1, 4, 8Hushan Yuan 3

1The University of Sydney, Faculty of Science, School of Physics, Sydney, NSW, Australia; 2Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, Australia; 3Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 4Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia; 5The Institute for Innovation in Imaging and the A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; 6Bouve College of Health Sciences, CaNCURE Program, Northeastern University, Boston, MA, USA; 7Internal Medicine Residency Program, Lahey Hospital and Medical Center, Burlington, MA, USA; 8The University of Sydney Nano Institute, Sydney, NSW, Australia

Correspondence: Hushan YuanGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 149 13 th Street, Charlestown, MA 02129, USATel +1 617-643-1963Email hyuan@mgh.harvard.edu

Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), a drug approved for the treatment of iron anemia.Material and methods: FH NPs were heated (120C) with nonradioactive metals, the resulting metal-FH NPs were characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), and r 1 and r 2 relaxivities obtained by nuclear magnetic relaxation spectrometry (NMRS). In addition, the HIR method was performed with [ 90Y]Y 3+, [ 177Lu]Lu 3+, and [ 64Cu]Cu 2+, the latter with an HIR technique optimized for this isotope. Optimization included modifying reaction time, temperature, and vortex technique. Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and thin-layer chromatography (TLC).Results: With ICP-MS, metals incorporated into FH at high efficiency were bismuth, indium, yttrium, lutetium, samarium, terbium and europium (> 75% @ 120 oC). Incorporation occurred with a small (less than 20%) but statistically significant increases in size and the r 2 relaxivity. An improved HIR technique (faster heating rate and improved vortexing) was developed specifically for copper and used with the HIR technique and [ 64Cu]Cu 2+. Using SEC and TLC analyses with [ 90Y]Y 3+, [ 177Lu]Lu 3+ and [ 64Cu]Cu 2+, RCYs were greater than 85% and RCPs were greater than 95% in all cases.Conclusion: The chelate-free HIR technique for binding metals to FH NPs has been extended to a range of metals with radioisotopes used in therapeutic and diagnostic applications. Cations with f-orbital electrons, more empty d-orbitals, larger radii, and higher positive charges achieved higher values of RCY and RCP in the HIR reaction. The ability to use a simple heating step to bind a wide range of metals to the FH NP, a widely available approved drug, may allow this NP to become a platform for obtaining radiolabeled nanoparticles in many settings.

Keywords: nanomedicine, radiolabeling, radionuclide therapy, HIR, Feraheme

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press

Read More...

The application of technology in the fields of medicines and living sciences – BPhrm Dv

January 8th, 2020 11:44 pm

There are some fascinating possibilities for using nanotechnology in medicine. Some techniques are only imagined, while others are being tested at different stages.

The nanotechnology field of medicine includes applications of currently-developed nanoparticles and longer-range work involving the use of engineered nano-robots to repair cellularly (sometimes called nanomedicine).

Regardless of what you call nanotechnology, it can revolutionize the manner in which we diagnose and treat human corporal and disease damage in the future, and many technologies only imagined a few years ago, are making significant progress towards becoming reality.

A report on the opportunities offered by nanobiotechnology was published by the German pharmaceutical group, VFA.

The report found that Germany holds a strong position with 1,100 companies in space, including nanobiotechnology, the application of technology in the fields of medicines and living sciences, in the area of nanotechnology.

The relatively young research field has the potential to further improve diagnostic and therapeutic chances for diseases which had not or can not have previously been treated sufficiently Currently used in medical and pharmaceutical nanobiotechnological methods include high-data screening to seek new targets structures and substances, alongside the use of nanotechnology

Many nano-cancer therapies as medical devices for the treatment of brain and liver tumors have also been approved since 2010. Many other nano-based life science technologies are currently being developed in different stages.

The VFA supports a rise in nanobiotechnology technical leadership, exploiting the potential of nanomedicine and actively promoting nanomedicine, believing that this is a major advantage for patients.

The still very recent field of research can further enhance the diagnostic and therapeutic prospects for previously incurable or not adequately treatable diseases, explains a concluding statement from the VFAs view of this topic.

Public discussion will continue to highlight the huge opportunities provided by nanobiotechnology and nanobiotechnology applications that patients already can gain from today, the statement says.

The overall aim must be to consider and overcome concerns about this new technology on a large societal basis.

Whatwe'vecaterpillar-trackedand seenwithin thelast four yearsmay be aspiritedscheme,thatwaswithin thepast,terriblye-commerce health-centered totoday,terriblysubtlewith AI drug discovery, clinical trials, and digitalmedicine, etc. In 2018,the wholequantityofcapitalthat wasendowedin the Asia Pacific amounted toconcerning$6.8B.To placein context,within theUSits$8.2B and $2B for Europe,aforesaidJulien de Salaberry, Chiefmilitary officer& Founder,anatomistGrowth Asia

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

DNA play an important part in humans and their development. DNAs are the core reason behind everything in our life. It shapes our body, functions, features and even the capability of receiving certain diseases. The core of DNAs has not

Read more:
The application of technology in the fields of medicines and living sciences - BPhrm Dv

Read More...

What are the Upcoming Trends of Nanotechnology in Medicine? – Medical Tech Outlook

January 8th, 2020 11:44 pm

Nanotechnology is a rapidly expanding area of research with massive potential in many sectors ranging from healthcare to construction, and electronics.

FREMONT, CA: In the field of medicine, nanotechnology has revolutionized drug delivery, gene therapy, diagnostics, and various other areas of research, development and clinical application. Nanotechnology is a leading technology in medicine, bettering the potential of nanotechnology to target specific cells or tissues is a popular area of interest for the companies producing nanomedicines. Numerous registered clinical trials are in progress and involve nanotechnology; many of these studies are related to oncology and other therapy areas such as autoimmune diseases, anti-fungal agents and rare diseases. Playing a significant role in the transformation of medicine, identifying the trends in nanotechnology industry is essential.

Target Specification

The area of medicinal research involves attaching nanoparticles into drugs or liposomes to enhance specific localization. Different cell types have remarkable properties, and nanotechnology can be used to recognize cells of interest. This method enables associated drugs and therapeutics to reach diseased tissue while bypassing healthy cells.

Controlled Drug Release

The capability to control the discharge of a drug or therapeutic compound from its associated nanotechnology is benefitting a lot of interest from the industry. This triggered release can be gained from inside the body or from outside the body. The internal system consists of changes in the ecosystem of tumours in comparison with the surrounding tissues, while external stimuli comprise temperature change, ultrasound, or light. At present, the research efforts are dedicated to trying to understand how to release diagnostic molecules and drugs from liposomes with heat, and microbubbles using ultrasound.

Understanding Varied Patient Populations

Generally, there is a need for a better understanding of what makes patients distinctive from each other in terms of lack of ubiquitous drug efficacy. This raises a question, why nanotechnologies are not always able to improve the therapeutic output of drugs for an individual patient. Understanding the behaviour of nanomedicines when encountering different physiological characteristics of the patients and their disease states is significant.

Production of Nanomedicine

When compared to standard drug compounds, synthesizing and producing nanomedicine is primarily believed to be more complicated. In a few cases, this can limit the potential of drug manufacturers or pharmaceutical companies to deliver large quantities of nanomedicines. Not addressing the issues related to production may make the companies less interested in investing resources in this industry.

Follow this link:
What are the Upcoming Trends of Nanotechnology in Medicine? - Medical Tech Outlook

Read More...

NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update – Yahoo Finance

January 8th, 2020 11:44 pm

Regulatory News:

"After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given NBTXR3s universal mode of action, our proof-of-concept in soft tissue sarcoma, and promising results from our phase I trial in head and neck cancers, we are confident that NBTXR3 activated by radiation therapy has the potential to significantly improve treatment outcomes for head and neck cancer patients. Beyond head and neck, we will continue to expand into additional indications and combination therapies. Ultimately, we aim to change the oncology treatment paradigm for millions of patients around the world." Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext : NANO ISIN : FR0011341205 the Company) today announced its global development strategy for 2020 and beyond, following proof-of-concept (POC) and European market approval for NBTXR3 in locally advanced soft tissue sarcoma of the extremities and trunk wall (Brand Name: Hensify) in 2019. The Company will continue to prioritize its registration pathway in the US and EU for the treatment of head and neck cancers, while also working to advance the Nanobiotix immuno-oncology (I/O) program and evaluate NBTXR3 in other indications such as lung, pancreatic, esophageal, hepatocellular carcinoma (HCC), prostrate, and rectal cancers. To execute this plan, Nanobiotix will focus on H&N cancers while its collaborators (i.e. The University of Texas MD Anderson Cancer Center (MD Anderson) in the US and PharmaEngine in Asia) are working on other indications.

Global Development Plan Visualization

TRIAL

STATUS

ANTICIPATED NEXT STEPS

Development in Head and Neck Moving Forward

Phase III Registration Trial for NBTXR3 in head and neck patients ineligible for cisplatin

TRIAL NAME: STUDY 312

Nanobiotix trial

Design completed based on last interactions with FDA and European payers (EUnetHTA)

Jan 2020 - Submission of final protocol to FDA and other global regulatory bodies

Phase I and Phase I Expansion Trial for NBTXR3 in head and neck patients ineligible for cisplatin or intolerant to cetuximab

TRIAL NAME: Study 102/ 102 Expansion

Nanobiotix trial

Phase I dose escalation completed / data reported 19 patients

Dose Expansion 38 of 44 patients recruited

Q1 2020 - Update of dose escalation patients follow-up

Mid 2020 - First expansion phase data on efficacy and safety of dose expansion

Phase I/II Trial for NBTXR3 combined with cisplatin for head and neck patients

TRIAL NAME: PEP503-HN-1002

PharmaEngine trial

3rd dose level recruiting

H2 2020- Last patient in for 5th (last) dose level

Immuno-Oncology Program with NBTXR3

Phase I Basket Trial for NBTXR3 combined with pembrolizumab or nivolumab in H&N, lung metastasis, liver metastasis patients

TRIAL NAME: Study 1100

Nanobiotix trial

First patients treated

Protocol extended to include patients with lung and liver metastases from any primary tumor. Recruitment ongoing

Mid-year 2020 - first data reported

Phase II Trial of reirradiation with NBTXR3 combined with anti-PD-1/L1 for inoperable, locally advanced HN cancer

Phase II Trial for NBTXR3 combined with anti-PD-1 or anti-PD-L1 in Stage IV lung cancer

Phase I Trial for NBTXR3 combined with anti- CTLA4 and anti-PD-1 or PD-L1 in patients with advanced solid tumors and lung or liver mets

Phase II Trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression

MD Anderson trials

Final stage of protocol development

Q2-Q3 2020 - Submission of protocols to FDA

Development Across Other Indications

Phase I Trial for NBTXR3 in hepatocellular carcinoma and liver metastasis patients

TRIAL NAME: Study 103

Nanobiotix trial

Recruitment of the last patient at the 5th (last) dose level (one patient left to be treated)

Q1 2020 - Update on results

Phase I Trial for NBTXR3 in prostate cancer patients

TRIAL NAME: Study 104

Nanobiotix trial

2nd dose level recruiting

Q4 2020 - Update on results

Phase I Trial for NBTXR3 in pancreatic cancer

Phase I Trial for NBTXR3 in lung cancer patients in need of reirradiation

Phase I Trial for NBTXR3 in esophageal cancer patients

MD Anderson trials

Pancreas Regulatory process ongoing

Lung re-irradiation / Esophageal Submission of final protocol to regulatory process

Q2 2020 - First patient treated in pancreas

Q3 2020 - Lung re-irradiation / Esophageal first patient treated

Phase I/II Trial for NBTXR3 combined with chemotherapy in rectal cancer patients

TRIAL NAME: PEP503-RC-1001

PharmaEngine trial

4th (last) dose level recruiting

H2 2020 - Report phase I results

Next Steps in Soft Tissue Sarcoma

Phase III Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: Act.In.Sarc

Nanobiotix trial

Trial completed / data reported

H2 2020- Further follow up of the patients

Post-Approval Trial for NBTXR3 in soft tissue sarcoma of the extremities and trunk wall patients

TRIAL NAME: TBD

Nanobiotix trial

Design established (100 patients)

H2 2020 - Trial authorization by the relevant regulatory bodies expected

Development in Head and Neck Moving Forward

There are approximately 700,000 new head and neck cancer patients worldwide each year300,000 of these patients reside in the US and the European Union (EU) 1. Of these patients at diagnosis, 90% suffer from local disease and the remaining 10% have metastatic disease. 70-80% of all Head and Neck patients will receive radiation therapy, but significant unmet medical needs remain regarding either local control, systemic control, toxicity, or some combination of the three2. This is especially challenging for patients ineligible for platinum-based chemotherapy (cisplatin).

Global Registration Trial for NBTXR3 in Head and Neck Patients Ineligible for Cisplatin

As previously announced, Nanobiotix has begun interacting with the US Food and Drug Administration (FDA) on its regulatory pathway and met with the agency in October 2019 to refine the design elements of Study 312a phase III investigators choice, dual-arm, randomized (1:1) global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based chemotherapy (cisplatin).

More than half of head and neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease ordinarily requires aggressive, concerted measures. Due to potential comorbidities and toxicities associated with treatment, elderly and frail patients suffer from limited therapeutic options. Study 312 aims to target the unmet needs of this population.

Patients in the control arm will receive radiation therapy with or without cetuximab (investigators choice), and patients in the treatment arm will receive NBTXR3 activated by radiation therapy with or without cetuximab (investigators choice). The trial will recruit around 500 patients, the initial readout will be based on event-driven progression-free survival (PFS), and the final readout will be based on PFS and overall survival (OS). The study will be powered to demonstrate the OS superiority of NBTXR3 activated by radiation therapy. In addition, quality of life (QoL) will be measured as a key secondary outcome.

The Companys next step is to submit the final trial design to FDA and other global regulatory bodies within the month. A futility analysis is expected 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at 24-30 months, and final analysis will report on PFS and OS. In the event of favorable data from the initial readout, Nanobiotix plans to apply for conditional registration in the US.

Story continues

Confirming Efficacy with Phase I (Study 102) Expansion

Nanobiotix has already reported promising early signs of efficacy for patients with head and neck cancer through Study 1023 a phase I trial of NBTXR3 nanoparticles activated by intensity-modulated radiation therapy (IMRT) in the treatment of advanced-stage head and neck squamous cell carcinoma (HNSCC). The patient population for Study 102 includes elderly and frail patients who are ineligible for cisplatin or intolerant to cetuximab.

As a result of this report, the Company launched an expansion cohort with 44 additional patients to strengthen preliminary efficacy data. Recruitment for the expansion cohort has reached 38 of 44 patients and the initial readout is expected by mid-2020. Depending on the favorability of the final expansion phase data, the Company may seek to expedite the regulatory process in the EU.

Additional Development in Head and Neck with Collaborators

See more here:
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update - Yahoo Finance

Read More...

Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 – Instanews247

January 8th, 2020 11:44 pm

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018. This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

See the rest here:
Triple Negative Breast Cancer Treatment Market Is Expected To Expand US$ 720 Mn By 2026 - Instanews247

Read More...

Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 – Primo…

January 8th, 2020 11:44 pm

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Healthcare Nanotechnology (Nanomedicine) Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Healthcare Nanotechnology (Nanomedicine) Market during the forecast period 2015 2021.

As per the findings of the presented study, the Healthcare Nanotechnology (Nanomedicine) Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Healthcare Nanotechnology (Nanomedicine) in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/6370

The report segregates the Healthcare Nanotechnology (Nanomedicine) Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Healthcare Nanotechnology (Nanomedicine) Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Healthcare Nanotechnology (Nanomedicine) Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Healthcare Nanotechnology (Nanomedicine) Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/6370

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Link:
Growing Demand for Eco-friendly Products to Bolster the Growth of the Healthcare Nanotechnology (Nanomedicine) Market during 2015 2021 - Primo...

Read More...

Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra – Mumbai Live

January 8th, 2020 11:44 pm

First-of-its-kind in-house Pulverization Department was established at Bai Jerbai Wadia Hospital for Children which is now open for all needy patients in the city. FDA has given special permission and approval after the request from the Hospital. It was inaugurated by CEO Dr. Minnie Bodhanwala. Other dignitaries who were present on the occasion were Dr. S.S. Prabhu (Medical Director), Dr Suhas Pawar (Medical Superintendent), Dr Amjadkhan Pathan (Head Clinical Pharmacology).

Pulverization is the process of reduction of medicine dose as per the need of patients. It means to grind or crush medicines into fine particles and then dividing them into the required doses as per the requirement of the patient. This technique will be useful for non-coated tablets. In order to help paediatric patients enhance their quality of life, the hospital has come forward with a great move of opening a Pulverization Department at a minimal cost. A special nano weighing scale is used for the process of dose reduction.

Also Read:Childrens Day: Wadia Hospital Introduces India's First Therapy Park For Paediatric Patients In Hospital Premises

Dr Minnie Bodhanwala, Chief Executive Officer of the Wadia Hospitals, said,

Earlier, patients relative had to be in the queue for 2-3days, for getting the pulverized medicine (dose reduction) from outside facilities. Due to the delayed dose of medicine, many patients had prolonged hospitalization just waiting for the pulverized medicine from outside. After looking into this issue, the hospital decided to start the in house Pulverization department.

She added, Now, the FDA has given special permission and approval after the request from the hospital as the paediatric dosage is different from what is recommended to the adults. Usually, the medication dosage is dependent upon the weight of the patient and hence, the paediatric patient has very small dosages requirement. Neonatal patients unit also requires nano doses of medicine which is not available in the market. Therefore, the doctor advises reducing the dose into one- forth or one-eight part which is impossible for parents. However, this dose can be reduced by well-qualified pharmacists who can do the Pulverization in the sterile and aseptic areas. The hospital remains at the forefront of the latest technology and promises to give round-the-clock-care to the patients. We are committed to coming up with more such helpful initiatives for the benefit of the patients in the near future too.

Also Read:Nutrition Rehabilitation Centre Facility Introduced At Bai Jerbai Wadia Hospital For Children (BJWHC)

Read more:
Wadia Hospital For Children Launched A In-House Pulverization Department, First FDA Approved In Maharashtra - Mumbai Live

Read More...

Six City Honors grads in Jacobs School Class of 2023 – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

January 8th, 2020 11:43 pm

They spent their middle school and high school years with a firsthand view of the development of the burgeoning Buffalo Niagara Medical Campus, including the sparkling new downtown building that houses the Jacobs School of Medicine and Biomedical Sciences.

Now, amazingly, six graduates of City Honors School find themselves in the Class of 2023 at the Jacobs School.

These first-year students Hani Al-Jabi-Lopez, Lillian Dixon, James Ghosen, Fiona Hennig, Aleena Jafri and Joseph Nathanson are all alumni of the prestigious Buffalo school adjacent to the BNMC that routinely shows up in rankings of the best public schools in the state and even the country.

Hennig graduated from City Honors in 2012 and Dixon in 2015, while the others graduated in 2014. All six were enrolled in the International Baccalaureate Diploma Program, a program that prepares students in high school for the rigors of college.

City Honors is one of our stronger inner city schools, so its not a surprise that they are preparing students that eventually end up in medical school, says Dori R. Marshall, associate dean and director of admissions. Our hope is that we can help foster relationships with other high schools through our pipeline programs so the other Buffalo public schools also see that success with students.

The Jacobs School does not break out official statistics for the high schools its medical classes attended. However, James J. Rosso, admissions adviser in the Office of Medical Admissions, says that in the past 25 years, there have not been that many graduates of one high school in a single medical class at the Jacobs School.

The six are adjusting well, and have been impressed with the faculty and staff, and the new building that houses the medical school.

The professors and the deans really care about you doing well, and really try to help us out if were struggling, says Al-Jabi-Lopez, who earned bachelors degrees in behavioral biology and Spanish from Johns Hopkins University in 2018.

The facilities are also very impressive, adds Al-Jabi-Lopez, who plans to work in a clinical setting after residency and is also interested in academic medicine.

After graduating from Cornell University in 2016 with a bachelors degree in biology, Hennig moved to Oakland, Calif., and spent three years working and enjoying some time off before applying to medical school.

Therefore, all my fellow Centaurs (the schools mascot) were two or three grades below me in high school, she says. We knew of each other but now, being in the same medical school class, I have gotten to know each of them a little bit more.

I think it is no surprise that City Honors graduates excel in whatever they choose to pursue, she adds. I personally am very fortunate to have had many resources throughout my high school and undergraduate career, including a loving, supportive family.

The Jacobs School is also given high marks.

I really like the environment that the deans and faculty have created. I feel lucky to be in this high-tech facility, says Hennig, who has been especially impressed with the anatomy lab, which is not uncommon for current and prospective students.

After medical school, she hopes to pursue a surgical residency.

My goal is to become a surgeon specializing in gender-affirming surgeries for the LGBTQ+ community, she says. I hope to make an impact on the future of medical education and curriculum, and bring more awareness to LGBTQ+ health care wherever I end up.

Dixon, who earned bachelors degrees in molecular genetics and psychology from SUNY Fredonia in 2019, also finds the Jacobs School a nice fit.

The environment here is supportive and a lot more relaxed than other medical schools that Ive seen, she says. Its more focused on our health and happiness.

Ghosen and Nathanson have been good friends since they arrived at City Honors in fifth grade.

More than anything, City Honors prepares its students for the rigors of undergraduate life, and this in turn enables us to pursuecompetitive fields of study, Ghosen says. Many of the premedical students I met in college had never been exposed to such a large and difficult workload, and coming from City Honors, the transition wasnt as difficult.

Ghosen, who earned a bachelors degree in biology from SUNY Geneseo in 2018, enjoys the collaborative atmosphere at the Jacobs School.

The workload is definitely an adjustment from undergrad, but everybody in the class has been really great, he says. Its not cutthroat everybody kind of works together and that helps.

And he can think of nothing better than staying in his hometown after he gets his degree and completes his residency.

I definitely plan to practice in the Buffalo area, and could one day see myself teaching medical students from the Jacobs School, Ghosen says.

Thats music to Marshalls ears.

Whether they do their residency here or somewhere else, our hope is that they will come back here and make this their home because there is a physician shortage here, says Marshall, whos also an associate professor of psychiatry. We need our graduates to stay here and work.

Nathanson, who earned bachelors degrees in biological sciences and psychology from UB in 2018, appreciates the solid academic foundation that has prepared him for medical school.

I think that City Honors is second to none when it comes to preparing their students for furthering their education in an advanced setting, says Nathanson, who hopes to one day run his own medical practice. I was lucky enough to already know how to study before getting to college, and have carried some of those same techniques that I used in high school all the way to medical school.

Jafri, who earned a bachelors degree in biology from Cornell University in 2018, also likes being back in her hometown.

I chose the Jacobs School because of family and friends living in the city, because Buffalo is home, and also because this school offers a truly high-quality medical education with programs and opportunities in areas that are of interest to me, she says. The tremendous developmentof the surrounding medical complex and the many hospitals affiliated with the university were also a big plus.

They are continually making adjustments to the curriculum to improve the quality of our education and to cultivate a good environment that doesnt lead to burnout, Jafri adds.

William Kresse, principal at City Honors, says there has been an upswing in students from the school headed into STEM (science, technology, engineering and mathematics) fields over the past decade, and notes that City Honors has also expanded its intensive four-year science research program at the BNMC.

We are excited that so many of our alums are making their way to the Jacobs School, Kresse says.

More here:
Six City Honors grads in Jacobs School Class of 2023 - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Read More...

Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed – Discovery Institute

January 8th, 2020 11:43 pm

A new paper in Nature Reviews Genetics, Overcoming challenges and dogmas to understand the functions of pseudogenes, is simply incredible. It documents not only that pseudogenes have been found to have widespread function but also that under current dogma in biology, and given the technical limitations, we are failing to recognize their functions. As Seth W. Cheetham and his co-authors put it, biology suffers from demotivation into exploring pseudogene function by the a priori assumption that they are functionless where The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The abstract lays out exactly what they think:

Pseudogenes are defined as regions of the genome that contain defective copies of genes. They exist across almost all forms of life, and in mammalian genomes are annotated in similar numbers to recognized protein-coding genes. Although often presumed to lack function, growing numbers of pseudogenes are being found to play important biological roles. In consideration of their evolutionary origins and inherent limitations in genome annotation practices, we posit that pseudogenes have been classified on a scientifically unsubstantiated basis. We reflect that a broad misunderstanding of pseudogenes, perpetuated in part by the pejorative inference of the pseudogene label, has led to their frequent dismissal from functional assessment and exclusion from genomic analyses. With the advent of technologies that simplify the study of pseudogenes, we propose that an objective reassessment of these genomic elements will reveal valuable insights into genome function and evolution.

They immediately caution that there are many instances where DNA that was dismissed as pseudogene junk was later found to be functional: with a growing number of instances of pseudogene-annotated regions later found to exhibit biological function, there is an emerging risk that these regions of the genome are prematurely dismissed as pseudogenic and therefore regarded as void of function.

In 2003, Francisco Ayala and Evgeniy Balakirev wrote in Annual Review of Genetics that pseudogenes that have been suitably investigated often exhibit functional roles. This new Nature Reviews Genetics paper offers a very similar statement: Where pseudogenes have been studied directly they are often found to have quantifiable biological roles. Its a long narrative that recounts how many scientists mistakenly dismissed stretches of DNA as pseudogenes. They document dozens of instances where pseudogenes in humans and other organisms have been found to have function.

Some of these functions are protein-based, meaning the pseudogene actually generates a functional protein. But other functions can be RNA-based or DNA-based. For example, most evolutionists would presume that a pseudogene that does not produce a protein cant be functional. But the paper observes that pseudogenes that cannot be translated into a protein may still have a function through their RNA transcript:

Many pseudogenes contain a frequency of mutations that render them unlikely to be (or incapable of being) translated into proteins. However, such mutations do not necessarily preclude pseudogenes from performing a biological function.

The paper notes that even if the RNA transcript of a pseudogene cant be translated into protein, a myriad of RNA-based regulatory mechanisms have been described for pseudogenes, including processing into small interfering RNAs (siRNAs) that may regulate their parent genes, acting as a decoy for transcription factors and, most prominently, as molecular sponges for microRNAs.

Many evolutionists would forcefully assume that if a pseudogene cant even produce an RNA transcript then it cant be functional. But it turns out that pseudogenes that dont produce any RNA transcript (i.e., arent transcribed) can still have important functions:

Another mechanism through which pseudogenes can function is by influencing chromatin or genomic architecture. HBBP1, a pseudogene residing within the haemoglobin locus, enables the dynamic chromatin changes that regulate expression of fetal and adult globin genes during development. Notably, although inhibiting HBBP1 transcription has no effect, deletion of the genomic locus reactivates fetal globin expression. HBBP1 DNA contacts, but not transcription, are required for suppressing the expression of fetal globin genes in adult erythroid cells.

A variety of other non-transcriptional functions are documented in the paper, including stabilizing chromosomes, mediating transcript-splicing, and regulating recombination. Thus, in many cases copy numbers of pseudogenes seem to have functional importance, where deviations from the normal genetic state causes disease. They predict: It is expected that further links between human pseudogene polymorphisms and complex diseases will be identified in the coming years

The implication is that one reason we presume pseudogenes are functionless is because we havent been looking for their functions. And why didnt we look for their functions? Because we presumed they were functionless! So theres a circular aspect to the reasoning here. It has created the science-stopping junk-DNA paradigm, which has prevented us from understanding what pseudogenes really do.

The typical response from evolutionists would be that all of these examples of functional pseudogenes are just isolated rare cases, and that the bulk of pseudogenes are clearly junk. The authors of the paper who give no indication of sympathy for intelligent design, but definitely oppose dismissing pseudogenes as junk are aware of this objection. They say the following in direct rebuttal to it:

The examples of pseudogene function elaborated on here should not imply that pseudogene functionality is likely to be confined to isolated instances. At least 15% of pseudogenes are transcriptionally active across three phyla, many of which are proximal to conserved regulatory regions. It is estimated that at least 63 new human-specific protein-coding genes were formed by retrotransposition since the divergence from other primates. Numerous retrogenes continue to be recognized as functional protein-coding genes rather than pseudogenes across species. High-throughput mass spectrometry and ribosomal profiling approaches have identified hundreds of pseudogenes that are translated into peptides. Although the functions of these peptides remain to be experimentally determined, such examples illustrate the challenge in substantiating a genepseudogene dichotomy.

They continue: As the abundance of such [non-coding-DNA] acquired functions does not appear to be an especially rare or isolated phenomenon, it would seem remiss to take the default perspective that processed pseudogenes are functionless. Instead, it is probable that pseudogene-containing regions of the genome harbour important biological functions that are yet to be revealed.

They point out that current algorithmic and computational methods employed for differentiating pseudogenes and protein-coding genes may overestimate the proportion of the genome that is composed of pseudogenes. Why? Because the properties that are used to define many pseudogenes are also often found in normal protein-coding genes. For example:

Because of this, they argue that computational differentiation of pseudogenes from genes on a purely rule-based system is unlikely to be feasible as it will inherently conflict with many protein-coding genes. They therefore propose markedly softening claims that a stretch of DNA is a pseudogene: it may be useful to consider the annotation of pseudogenes in genomes as a prediction or a hypothesis rather than a classification.

As the authors show, the presumption that a pseudogene is functionless needs to be abandoned. But then, why are we still presuming they are functionless? There are three main reasons: (1) evolutionary thinking has presumed that pseudogenes are functionless junk, (2) terminological dogma reinforces a mindset that pseudogenic regions are intrinsically non-functional, and (3) technological limitations prevent us from discovering their function. The paper acknowledges that problem (3) stems from problem (2), but it fails to explicitly recognize that both problems (2) and (3) ultimately stem from problem (1). In fact it doesnt even identify problem (1) as a problem. Yet the whole situation traces back to bad evolutionary predictions. Lets look at these causes briefly, in reverse order:

The proximal cause that prevents us from understanding pseudogene functions are technological limitations. Because of the junk DNA paradigm, a lot of our biochemical techniques and technologies are set up only to identify standard protein-coding genes. They ignore and dismiss DNA that doesnt fit that mold. Only by updating our technology to detect functional DNA elements that dont necessarily fit the standard definition of a gene can be we begin to understand what pseudogenes really do. The paper explains that technical limitations, informed by our biases and assumptions, demotivate the study of pseudogene functions:

In addition to the demotivation into exploring pseudogene function by the apriori assumption that they are functionless, their systematic study has also been hindered by a lack of robust methodologies capable of distinguishing the biological activities of pseudogenes from the functions of the genes from which they are derived.

They compare the situation to that of long non-coding RNAs (lncRNAs), which were similarly dismissed initially as emanating from junk DNA or as transcriptional noise, largely by virtue of their definition as non-protein-coding. But as technology developed, lncRNAs are now widely recognized as functional and we regularly screen for their functions:

Following a combination of technology developments, genome-wide studies and detailed biochemical studies, lncRNAs are now routinely included in genome-wide analyses, and their functional potential as cellular regulators is widely recognized.

However, at present, the authors note, due in part to the experimental challenge of investigating their function and expression, pseudogenes are typically excluded from genome-wide functional screens and expression analyses. In other words, one of the main reasons we arent finding function for pseudogenes is because we arent looking for it. This needs to change, and they argue that it can.

For example, according to the paper, processed pseudogenes were presumed to have been rendered transcriptionally silent by the loss of cis-regulatory elements. But we now know that thousands of retrotransposed gene copies are transcribed and are often spliced into known protein-coding transcripts and up to 10,000 mouse pseudogenes have evidence of transcription. By trying to study these transcripts we can understand what they may be doing.

One complication is that pseudogene transcription shows cell-type specificity and dynamic expression meaning they may only be transcribed in particular places at particular times. This is all the more reason not to assume that lack of evidence for the function of a pseudogene is evidence that the pseudogene has no function! It very likely may be functional in a cell-type or a situation that we just havent properly investigated yet. As they put it, The use of assays ill-suited to analysis of pseudogenes has arguably stymied elucidation of their biological roles. But they are hopeful: CRISPR-based approaches, carefully applied, have the potential to revolutionize our ability to dissect the functions of pseudogenes. They conclude that its time to stop excluding pseudogenes from biochemical analyses and start using techniques that can identify their functions:

The use of a liberal definition of pseudogenes is attractive as it simplifies genomic analyses. This approach, often unknowingly to the researcher, leads to the consolidation of the pseudogene classification that is, their exclusion by convenience in functional studies. Many regions now considered to be dead genes potentially encode cis-regulatory elements, non-coding RNAs and proteins with impacts in human biology and health. Accordingly, determining the functions of putative pseudogenes warrants active pursuit by their inclusion in functional screens and analyses of genomic, transcriptomic and proteomic data. With innovations in long-read sequencing and CRISPR-based methodologies now readily accessible, the technological limitations that formerly motivated the exclusion from functional investigation are largely resolved.

Until we develop and apply these technologies to put pseudogenes to the proper test, the assumption that they are functionless junk is completely unwarranted. And its not hard to predict what the outcome will be. As Ayala and Balakirev noted, pseudogenes that have been suitably investigated often exhibit functional roles. Or as this new paper observes, Where pseudogenes have been studied directly they are often found to have quantifiable biological roles.

Technology only reflects what people want to do, and there are reasons why biologists have created hardly any technology to investigate pseudogenes: biologists presume (wrongly) that pseudogenes are nonfunctional junk. The paper argues that the terminology associated with the junk DNA paradigm discourages investigation into their function. Thus, we have terms like pseudogene which by their very nature imply that the DNA isnt a gene but something like a wannabe gene that doesnt do anything. As the authors note, the definition of a pseudogene as defective means the non-functionality of pseudogenes remains the dominant and default perception. Citing Thomas Kuhn and his concept of a dominant paradigm that is intolerant of criticisms, they lash the junk-pseudogene paradigm in strong terms:

[T]he term pseudogene itself asserts a paradigm of non-functionality through its taxonomic construction. Pseudogenes are defined as defective and not genes. This point is highlighted because impartial language in science is known to inherently restrict the neutral investigation between conflicting paradigms. In the case of pseudogenes, the term itself is constructed to support the dominant paradigm and therefore limit, consciously or unconsciously, scientific objectivity in their investigation.

Its hard to imagine a greater indictment of the idea that pseudogenes are generally functionless. They continue to explain how use of the term pseudogene hinders scientific research:

Although the pseudogene concept arose to describe an individual molecular phenomenon, the term was rapidly adopted to annotate tens of thousands of genomic regions that met only loosely defined criteria and was effectively axiomatized without being subject to any rigorous scientific debate. This lack of consensus-seeking process has left genome biology with a legacy concept that obscures objective investigation of genome function.

They recommend using different language where [t]he automated classification of gene-like sequences as pseudogenes should be avoided. Instead, we propose that descriptive terms that do not make functional inferences should be used in reference to genomic elements that arose from gene duplication and retrotransposition and terminology should not impose any unsubstantiated assumption on end users.

So what is now stopping us from elucidating the functions of pseudogenes? The only obstacle is a mental block not a technical or evidential one:

The dominant limitation in advancing the investigation of pseudogenes now lies in the trappings of the prevailing mindset that pseudogenic regions are intrinsically non-functional.

The paper predicts that as soon as we lose this mindset, there will remain no technical limitations blocking us from progress in understanding the functions of pseudogenes: With renewed scientific objectivity, we anticipate that a wealth of discoveries to understand genome function, its role in disease and the development of new treatments is within reach.

Thats good news, but we must ask a question the paper fails to ask: Why did this terminology develop in the first place?

Evolutionary thinking is the cause that ultimately created, nurtured, and sustained the junk DNA paradigm. Yet the paper adopts a wholly evolutionary approach, and for this reason never identifies evolutionary thinking as the root problem. The closest the authors get is when they recount how the very first paper to identify a pseudogene (published in 1977) dismissed its potential function as a relic of evolution:

In the absence of evidence that the 5S pseudogenes were transcribed, Jacq etal. concluded that the most probable explanation for the existence of the pseudogenes is that they are a relic ofevolution and are functionless1. Since the coining of the term pseudogene, its definition has broadened and is now widely accepted to define any genomic sequence that is similar to another gene and is defective.

This 1977 paper by Jacq et al. was published in the journal Cell and found a pseudogene in an African frog. That paper concluded:

We are thus forced to the conclusion that the most probable explanation for the existence of the pseudogene is that it is a relic of evolution. During the evolution of the 55 DNA of Xenopus laevis, a gene duplication occurred producing the pseudogene. Presumably the pseudogene initially functioned as a 55 gene, but then, by mutation, diverged sufficiently from the gene in its sequence so that it was no longer transcribed into an RNA product.

And there you have it: The pseudogene is seen as a mere a relic produced by mutation until it diverged so much that it was no longer transcribed into an RNA product. This is the classic view of a pseudogene.

Ironically, the 1977 paper went on to speculate that perhaps there is evidence for function for the pseudogene, but the authors privilege the relic view as the right answer until a function can be proven:

This evolutionary explanation for the presence of the pseudogene, however, is incomplete by itself in that it ignores the conservation in sequence of the pseudogene, and indeed of the entire G + C-rich spacer of 55 DNA. In an attempt to explain this, it has been suggested that the pseudogene may be a transcribed spacer corresponding to a primary transcript of 55 RNA, which is a transient precursor and has not so far been detected. If this is so, then most of the G + C-rich region of 55 DNA would be the structural gene for 5S RNA. This function, if true, would provide the necessary selective pressure to conserve the sequence of the linker and pseudogene region so that the correct processing of the postulated 300-long precursor was maintained. In the absence of any experimental evidence for such a long precursor, however, this suggestion must be regarded as speculative; it is more probable that the pseudogene is a relic of evolution.

The recent Nature Reviews Genetics paper hopes to remedy this problem by reviewing much of the overwhelming evidence for pseudogene function and emphasizing how the the non-functionality of pseudogenes remains the dominant and default perception. This will limit, consciously or unconsciously, scientific objectivity in their investigation. The authors are to be commended. However, experience teaches that unless you address the root cause of a problem, it rarely goes away. The tendency to view pseudogenes as a relic of evolution probably wont change as long as you presume that the entire genome is the product of blind evolution. The paper fully endorses the latter view, providing all kinds of narrative gloss that describes pseudogenes (whether functional or not) as retrocopies that arose from gene duplication and transposition. They emphasize:

In the fundamental reductionist approach often assumed in genetics and molecular biology, the perspective is often lost that life as we observe it today is not only the product of billions of years of evolutionary processes but also still subject to these same processes.

They are welcome to take the reductionist approach often assumed in genetics and molecular biology. But until those fundamental evolutionary views of the genome are on the table for questioning, they wont make much progress in shaking the science-stopping assumptions of the junk-DNA paradigm.

Photo: Xenopus laevis, by Brian Gratwicke [CC BY 2.0], via Wikimedia Commons.

Excerpt from:
Nature Reviews Genetics Pseudogene Function Is Prematurely Dismissed - Discovery Institute

Read More...

Scientists link mysterious snippets of DNA to cell growth and tumor suppression – GeekWire

January 8th, 2020 11:43 pm

Its been 80 million years since our our evolutionary branch diverged from mice so why do we share some fragments of DNA that are essentially unchanged? (Fred Hutch News Service Illustration / Kim Carney)

Why do some strings of genetic code remain virtually unchanged despite tens of millions of years of evolutionary divergence? A newly published study that takes advantage of the gene-editing technique known as CRISPR has found that at least some of those DNA strings are essential to keep healthy cells growing and block the growth of tumor cells.

The research, published today in Nature Genetics, is the first study finding large-scale importance of these highly conserved elements, senior author Rob Bradley of Seattles Fred Hutchinson Cancer Research Center said in a news release.

Bradley and his colleagues say unraveling the mysteries of those ultra-conserved elements could lead to new avenues for cancer treatment.

The study started out with a molecular analysis focusing on specialized snippets of DNA known as poison exons. Such snippets regulate the activity of cells by shutting off the production of particular proteins. Theyve been called kill switches for cellular functions. When they go haywire, they can cause maladies such as epilepsy. But when they work the way theyre supposed to, they can poison the production of undesirable proteins and keep cells on the right track.

Scientists have previously noticed an overlap between poison exons and ultra-conserved elements, but they puzzled over why the poison exons were so essential that theyve been relatively untouched by evolutionary pressures. In order to solve the puzzle, the Fred Hutch team made use of a CRISPR gene-editing enzyme that was modified with guide-RNA molecules to hunt down and snip out hundreds of poison exons from the DNA code in human cells.

Bradley and the studys lead author, Fred Hutch researcher James Thomas, call their technique paired guide RNAs for alternative exon removal, or pgFARM (pronounced like pig farm). Whats unique about what James did is not the approach per se, but that hes doing it in high throughput, Bradley said.

The researchers identified 465 poison exons that were highly conserved in humans, mice and rats as well as another 91 poison exons that werent so highly conserved. When they knocked out the ultra-conserved exons in cells that were grown in a lab dish, the cells died off.

As a follow-up, the team tested the role of poison exons in live mice that had lung tumors. Many of the exons were essential for normal cell growth, just as they were for the cells in the lab dish. Even more intriguingly, some of the exons had tumor-suppressing effects that were clinically relevant, the researchers reported.

Tumor-fighting poison exons tended to turn up within the genes that govern RNA splicing, a vital part of the cells protein-making machinery. Those exons may well rein in RNA-splicing factors that could otherwise promote tumor growth.

Scientists are already working on techniques to fix RNA-splicing problems that contribute to a wide variety of diseases and Thomas is hopeful that ultra-conserved poison exons could point the way to new molecular targets specific to cancer treatment.

Once you find a target, its easy to build upon the previous technology that exists for therapeutics, he said.

Update for 6:15 p.m. PT Jan. 8: Weve fine-tuned this report to describe the procedures used in the experiment more accurately. In addition to Thomas and Bradley, the authors of the Nature Genetics study, RNA Isoform Screens Uncover the Essentiality and Tumor-Suppressor Activity of Ultraconserved Poison Exons, include Jacob Polaski, Qing Feng, Emma De Neef, Emma Hoppe, Maria McSharry, Joseph Pangallo, Austin Gabel, Andrea Belleville, Jacqueline Watson, Naomi Nkinsi and Alice Berger.

See the rest here:
Scientists link mysterious snippets of DNA to cell growth and tumor suppression - GeekWire

Read More...

Sight loss research needs urgent investment – The Guardian

January 8th, 2020 11:43 pm

As leading ophthalmologists and researchers we are joining the eye research charity Fight for Sight to call for urgent action on blindness in 2020 to address the research funding gap.

We know that serious sight loss doesnt discriminate it can affect anyone at any time and it is on the increase. Science can already do so much and with the advent of new gene therapies and stem cell treatments we are so close to outcomes that were not possible a decade ago. Yet so much more needs to be done to develop new universal treatments.

The main barrier is the lack of research funding. It is unacceptable that in 2020 only 1% of UK grant funding goes to eye research, even though more than 20% of people will be affected by serious sight loss in their lifetime. Blindness can have a huge impact on peoples mental health and ability to work, increasing costs on health systems and infrastructure.

In 2019 the WHO and UN general assembly both outlined that globally more investment is needed into sight loss and research. We are calling for the new government and its partners to agree a national plan on sight loss and a research agenda that will help to ensure that eye research gets the funding it badly needs. Please join us at fightforsight.org.uk and let 2020 be the year that we accelerate progress in beating blindness.

Prof Chris Hammond Frost chair of ophthalmology, Kings College London, Prof Alan Stitt Dean of innovation and impact, Queens University Belfast, Prof Alastair Denniston Consultant ophthalmologist, Birmingham University, Prof Alison Hardcastle Professor of molecular genetics, UCL Institute of Ophthalmology, Prof Lynda Erskine Chair in developmental neurobiology, Aberdeen University, Prof Jeremy Guggenheim Director of research, Cardiff University, Prof David Steel Consultant ophthalmologist, Newcastle University, Prof Chris Inglehearn Professor of molecular ophthalmology and neuroscience, Leeds University, Prof Timothy Jackson Consultant ophthalmic surgeon, Kings College London, Prof Rachael Pearson Professor of developmental neuroscience, UCL Institute of Ophthalmology, Prof Jessica Teeling Professor of Experimental Neuroimmunology, University of Southampton, Prof Colin Willoughby Professor of ophthalmology, Ulster University

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

Do you have a photo youd like to share with Guardian readers? Click here to upload it and well publish the best submissions in the letters spread of our print edition

Go here to see the original:
Sight loss research needs urgent investment - The Guardian

Read More...

Page 737«..1020..736737738739..750760..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick